123 related articles for article (PubMed ID: 15454848)
1. Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model.
Odenstedt J; Månsson C; Grip L
J Cardiovasc Pharmacol; 2004 Oct; 44(4):407-15. PubMed ID: 15454848
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II.
Segawa D; Sjöquist PO; Wang QD; Gonon A; Rydén L
J Cardiovasc Pharmacol; 2002 Sep; 40(3):339-45. PubMed ID: 12198319
[TBL] [Abstract][Full Text] [Related]
3. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine.
Segawa D; Sjöquist PO; Wang QD; Gonon A; Nordlander M; Rydén L
J Cardiovasc Pharmacol; 2000 Sep; 36(3):338-43. PubMed ID: 10975591
[TBL] [Abstract][Full Text] [Related]
4. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.
Gourine A; Gonon A; Sjöquist PO; Pernow J
Cardiovasc Res; 2001 Jul; 51(1):100-7. PubMed ID: 11399252
[TBL] [Abstract][Full Text] [Related]
5. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide.
Gourine AV; Pernow J; Poputnikov DM; Sjöquist PO
J Cardiovasc Pharmacol; 2002 Oct; 40(4):564-70. PubMed ID: 12352318
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Wang QD; Segawa D; Ericsson H; Sjöquist PO; Johansson L; Rydén L
J Cardiovasc Pharmacol; 2002 Aug; 40(2):228-34. PubMed ID: 12131552
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A, 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion.
Karlsson LO; Bergh N; Grip L
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):159-63. PubMed ID: 21572075
[TBL] [Abstract][Full Text] [Related]
8. Experimental parameters and infarct size in closed chest pig LAD ischemia reperfusion models; lessons learned.
Silvis MJM; van Hout GPJ; Fiolet ATL; Dekker M; Bosch L; van Nieuwburg MMJ; Visser J; Jansen MS; Timmers L; de Kleijn DPV
BMC Cardiovasc Disord; 2021 Apr; 21(1):171. PubMed ID: 33845779
[TBL] [Abstract][Full Text] [Related]
9. Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model.
Tadokoro H; Miyazaki A; Satomura K; Rydén L; Kaul S; Kar S; Corday E; Drury K
J Cardiovasc Pharmacol; 1996 Jul; 28(1):134-41. PubMed ID: 8797147
[TBL] [Abstract][Full Text] [Related]
10. Role of Na(+)-H+ exchange on reperfusion related myocardial injury and arrhythmias in an open-chest swine model.
Fukuta M; Wakida Y; Iwa T; Uesugi M; Kobayashi T
Pacing Clin Electrophysiol; 1996 Nov; 19(11 Pt 2):2027-33. PubMed ID: 8945091
[TBL] [Abstract][Full Text] [Related]
11. Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Shimizu M; Wang QD; Sjöquist PO; Rydén L
J Cardiovasc Pharmacol; 1999 Oct; 34(4):512-7. PubMed ID: 10511125
[TBL] [Abstract][Full Text] [Related]
12. Opioid receptor agonist Eribis peptide 94 reduces infarct size in different porcine models for myocardial ischaemia and reperfusion.
Karlsson LO; Grip L; Bissessar E; Bobrova I; Gustafsson T; Kavianipour M; Odenstedt J; Wikström G; Gonon AT
Eur J Pharmacol; 2011 Jan; 651(1-3):146-51. PubMed ID: 21093430
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular unloading with intra-aortic counter pulsation prior to reperfusion reduces myocardial release of endothelin-1 and decreases infarction size in a porcine ischemia-reperfusion model.
LeDoux JF; Tamareille S; Felli PR; Amirian J; Smalling RW
Catheter Cardiovasc Interv; 2008 Oct; 72(4):513-21. PubMed ID: 18814226
[TBL] [Abstract][Full Text] [Related]
14. Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery.
García-Ruiz JM; Galán-Arriola C; Fernández-Jiménez R; Aguero J; Sánchez-González J; García-Alvarez A; Nuno-Ayala M; Dubé GP; Zafirelis Z; López-Martín GJ; Bernal JA; Lara-Pezzi E; Fuster V; Ibáñez B
Basic Res Cardiol; 2017 Mar; 112(2):17. PubMed ID: 28188434
[TBL] [Abstract][Full Text] [Related]
15. Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration.
Yetgin T; Uitterdijk A; Te Lintel Hekkert M; Merkus D; Krabbendam-Peters I; van Beusekom HMM; Falotico R; Serruys PW; Manintveld OC; van Geuns RM; Zijlstra F; Duncker DJ
JACC Cardiovasc Interv; 2015 Dec; 8(15):1990-1999. PubMed ID: 26738671
[TBL] [Abstract][Full Text] [Related]
16. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size.
Herzog WR; Vogel RA; Schlossberg ML; Edenbaum LR; Scott HJ; Serebruany VL
Int J Cardiol; 1997 Mar; 59(1):21-7. PubMed ID: 9080022
[TBL] [Abstract][Full Text] [Related]
17. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
Mizumura T; Nithipatikom K; Gross GJ
Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion.
Han B; Zhang X; Zhang Q; Zhao G; Wei J; Ma S; Zhu W; Wei M
Arch Cardiovasc Dis; 2011 May; 104(5):313-24. PubMed ID: 21693368
[TBL] [Abstract][Full Text] [Related]
19. Clevidipine: a review of its use in the management of acute hypertension.
Deeks ED; Keating GM; Keam SJ
Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
[TBL] [Abstract][Full Text] [Related]
20. Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist.
Hohlfeld T; Braun M; Strobach H; Schrör K
J Cardiovasc Pharmacol; 1994 Jun; 23(6):922-31. PubMed ID: 7523784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
